Buscar

26/03/2026 Evaluating the added value of a multifactorial model over gene-based risk estimates in breast cancer prediction for healthy carriers of pathogenic variants
Garcia, AM, Rezqallah-Arón, A, Duran-Lozano, L, López-Fernández, A, Darder, E, Alfonso, R, Cartró, M, Cruellas, M, Reig-Jané, J, Roqué, A, Tuset, N, Cajal, TRY, Brunet, J, Balmaña, J. Evaluating the added value of a multifactorial model over gene-based risk estimates in breast cancer prediction for healthy carriers of pathogenic variants. EUROPEAN JOURNAL OF CANCER. 2026; 237DOI:10.1016/j.ejca.2026.116560. PMID:. IF:7.100(Q1/2D).
01/03/2026 Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.
Villarrubia, JE, Fita, MJJ, de Liaño, AG, Cerrillomd, JM, Cruz, P, Anguera, G, Puente, J, Torras, OR, Navarro-Gorro, N, Pinto, A, Ruiz, SG, Cacho, D, Maeso, IG, González, NS, Lainez, N, Herranz, UA, Carrera-Lasfuentes, P, Climent, MA, Macías, NR, Castellano, D. Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.700. PMID:. IF:41.900(Q1/1D).
12/03/2026 IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
Martin-Broto, J, Strauss, SJ, Palmerini, E, Valverde, C, Sebio, A, Redondo, A, Stacchiotti, S, Grignani, G, Aliberti, S, Diaz-Beveridge, R, Billalabeitia, EG, Cruz, J, Carrasco-Garcia, I, Ibrahim, T, Diaz-Martin, J, Salguero-Aranda, C, Gutierrez, A, Mayordomo-Aranda, E, Ramos, R, Merino, J, Collini, P, Tirabosco, R, Bague, S, Romagosa, C, Carrera, MA, Ledesma, P, Hindi, N, Moura, DS. IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. Cancer Communications. 2026; 46DOI:10.34133/cancomm.0015. PMID:41836677. IF:24.900(Q1/1D).
01/04/2026 Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy
Holgado, A, Llansana, A, Vázquez, C, Gallego, O, Aguado, M, Valero, C, León, X. Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy. ORAL ONCOLOGY. 2026; 175DOI:10.1016/j.oraloncology.2026.107903. PMID:41722172. IF:3.900(Q1/2D).
01/03/2026 SEOM-AEEMT consensus on occupational cancer and cancer-associated disability
Mezquita, L, Vicente-Herrero, MT, Cruz, P, de la Torre, MVRI, Hidalgo-Coloma, J, Garcia, LC, Gallego, O, Calvo, A, Martinez, K, Perez-Altozano, J, Molina, R, Garcia-Pardo, M, Gutierrez-Sainz, L, Moreno-Atahonero, E, Ore-Arce, M, Serrano, C, Terradillos-Garcia, MJ, Valero, MR, Reinoso-Barbero, L, Rodriguez, CA, Calvo-Cerrada, B. SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-025-04037-2. PMID:40956506. IF:2.500(Q3/6D).
09/03/2026 Multidisciplinary Treatment of Inguinoscrotal Sarcomas: Analysis of 39 Cases Treated by Surgical Approach
Samsó, RH, Cabré, LC, Abós, SG, Solerdelcoll, MS, Majercakova, K, García, AS, Alegria, IG, Garrido, MF, Duarte, AM, López, JAG. Multidisciplinary Treatment of Inguinoscrotal Sarcomas: Analysis of 39 Cases Treated by Surgical Approach. Cancers. 2026; 18(5)DOI:10.3390/cancers18050876. PMID:41827809. IF:4.400(Q2/3D).